Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis):

Similar presentations


Presentation on theme: "Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis):"— Presentation transcript:

1 Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report Case Rep Ophthalmol 2016;7:389– DOI: / © 2016 The Author(s). Published by S. Karger AG, Basel - CC BY-NC 4.0

2 Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report Case Rep Ophthalmol 2016;7:389– DOI: / © 2016 The Author(s). Published by S. Karger AG, Basel - CC BY-NC 4.0

3 Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report Case Rep Ophthalmol 2016;7:389– DOI: / © 2016 The Author(s). Published by S. Karger AG, Basel - CC BY-NC 4.0

4 Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report Case Rep Ophthalmol 2016;7:389– DOI: / © 2016 The Author(s). Published by S. Karger AG, Basel - CC BY-NC 4.0


Download ppt "Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis):"

Similar presentations


Ads by Google